MarginsXMarginsX
Home › Markets › Health Care › XLO

Xilio Therapeutics Inc. (XLO)

XLO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.70
-3.08% on the day
Market cap
$54.4M
Micro cap
Revenue · 2025
$43.8M
+589.9% on 2024
Net income · 2025
-$35.0M
-80.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1840233/000119312526118550/0001193125-26-118550-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerXLO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001840233
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$43.8M
Net income-$35.0M
Operating income-$42.0M
Net margin-80.1%
Operating margin-95.9%
Revenue growth+589.9%
Cash$137.5M
Total assets$154.7M
P/E (computed)Net income was not positive
P/S (computed)1.2×

Warning signs

Cash runway
25.8 months
$122.2M cash at September 30, 2026
Share count, 1 year
+88.4%
2025-11-11 to 2026-11-06 · +259.1% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$38K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$122.2M cash; operating cash flow -$14.2M a quarter.Report 2026-09-30
Shares outstanding7,063,982 (2026-11-06); 52,500,328 a year earlier; 27,542,000 three years earlier. 1y figure adjusted for split (1-for-14 overall); 3y figure adjusted for split (1-for-14 overall).Cover page 2026-11-06
Reverse splits, 3 years1; latest 1-for-14 on 2026-03-16Source 2026-03-16
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the marketLatest 2026-02-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $44K, sold $6K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$10.0M-$5.9M-$13.8M$122.2MNo debt tags$55.0M10-Q 2026-11-10
Q2 2026
2026-06-30
$18.7M-$6.4M-$18.8M$136.0MNo debt tags$64.1M10-Q 2026-08-12
Q1 2026
2026-03-31
$12.6M-$9.5M-$22.3M$150.3MNo debt tags$53.5M10-Q 2026-05-12
Q4 2025
2025-12-31
$13.7M$10.4M-$2.0M$137.5MNo debt tags$43.8M10-K 2026-03-23
Q3 2025
2025-09-30
$19.1M-$16.3M-$17.5M$103.8MNo debt tags$31.8M10-Q 2026-11-10
Q2 2025
2025-06-30
$8.1M-$15.8M-$14.5M$121.6MNo debt tags$15.0M10-Q 2026-08-12
Q1 2025
2025-03-31
$2.9M-$13.3M$29.0M$89.1MNo debt tags$9.3M10-Q 2026-05-12
Q4 2024
2024-12-31
$1.7M-$13.1M-$14.2M$55.3MNo debt tags$6.3M10-K 2026-03-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-05-12
Latest annual report10-K2026-03-23
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEF 14A2026-04-28

Source: SEC EDGAR submissions feed, 363 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.3%
1 month-12.4%
3 months-10.4%
Year to date-9.9%
1 year-17.8%
From 52-week high-28.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AZRAzora Therapeutics Inc.$3.81-6.85%$54.4M
INCRIntercure Ltd.$3.63-4.22%$54.5M
CINGCingulate Inc.$3.75-12.79%$54.5M
HRTXHeron Therapeutics Inc.$0.2843-8.44%$54.1M
VRCAVerrica Pharmaceuticals Inc.$3.20-10.11%$55.0M
SPROSpero Therapeutics Inc.$0.9464-5.35%$55.1M
TNXPTonix Pharmaceuticals Holding Corp.$2.88-4.32%$56.0M
CLNNClene Inc.$3.66-6.63%$52.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier